Table 1 Baseline characteristics of the whole cohort and divided by responder status
Characteristic | Data availability | All patients (n = 1050) | Responders (n = 601) | Non-responders (n = 449) |
|---|---|---|---|---|
Demographic and lifestyle factors | ||||
Female sex | 1050 (100) | 707 (67) | 398 (66) | 309 (69) |
Age (years) | 1050 (100) | 59 (49, 68) | 60 (49, 68) | 58 (48, 67) |
BMI (kg/m2) | 959 (91) | 27.5 (24.2, 31.6) | 27.4 (24.1, 31.1) | 27.9 (24.3, 33.0) |
Smoking: never | 1042 (99) | 420 (40) | 260 (44) | 160 (36) |
Smoking: former | 404 (39) | 232 (39) | 172 (39) | |
Smoking: current | 218 (21) | 104 (17) | 114 (26) | |
Alcohol consumption: current | 1030 (98) | 710 (69) | 401 (68) | 309 (71) |
Alcohol consumption: (units/fortnight) | 1009 (96) | 2 (0, 10) | 2 (0, 10) | 2 (0, 12) |
Coffee/tea consumption: (cups/day) | 815 (78) | 4 (3, 6) | 4 (2, 6) | 4 (3, 6) |
IMD score | 990 (94) | 13.9 (8.9, 24.5) | 13.7 (8.5, 23.7) | 14.8 (9.5, 27.2) |
Disease-specific factors | ||||
Symptom duration (months) | 1042 (99) | 9 (4, 28) | 8 (4, 24) | 10 (4, 33) |
RF positive | 889 (85) | 584 (66) | 354 (70) | 230 (60) |
Satisfied the 1987 ACR criteria | 962 (92) | 787 (82) | 470 (85) | 317 (77) |
HAQ score | 989 (94) | 1.1 (0.5, 1.6) | 1.1 (0.5, 1.8) | 1.0 (0.4, 1.5) |
Co-morbidities: 0 | 1050 (100) | 392 (37) | 240 (40) | 152 (34) |
Co-morbidities: 1 | 345 (33) | 189 (31) | 156 (35) | |
Co-morbidities: 2+ | 313 (30) | 172 (29) | 141 (31) | |
Creatinine (mg/dl) | 970 (92) | 67 (59, 77) | 66 (58, 76) | 67 (60, 79) |
Disease activity | ||||
Morning stiffness (minutes) | 1000 (95) | 60 (15, 120) | 60 (20, 120) | 60 (10, 90) |
TJC28 | 1050 (100) | 6 (2, 13) | 8 (4, 15) | 4 (1, 10) |
SJC28 | 1050 (100) | 5 (2, 10) | 6 (3, 12) | 3 (1, 7) |
CRP (mg/l) | 1050 (100) | 5.6 (2.0, 16.2) | 8.2 (2.8, 21.4) | 3.8 (1.5, 9.9) |
Patient VAS (mm) | 1050 (100) | 41 (23, 60) | 47 (26, 66) | 32 (19, 50) |
DAS28-CRP | 1050 (100) | 4.3 (3.3, 5.3) | 4.7 (3.9, 5.7) | 3.7 (2.8, 4.6) |
DAS28-CRP ≤ 3.2 | 1050 (100) | 226 (22) | 64 (11) | 162 (36) |
DAS28-CRP ≤ 2.6 | 1050 (100) | 102 (10) | 12 (2) | 90 (20) |
Pain VAS (mm) | 971 (92) | 50 (28, 71) | 53 (30, 73) | 46 (25, 68) |
Fatigue VAS (mm) | 974 (93) | 54 (27, 73) | 54 (28, 74) | 53 (27, 72) |
Medication | ||||
Oral steroids: current | 1048 (100) | 210 (20) | 119 (20) | 91 (20) |
Intramuscular steroids: recent | 1028 (98) | 234 (23) | 137 (23) | 97 (22) |
Intra-articular steroids: recent | 882 (84) | 27 (3) | 14 (3) | 13 (3) |
Oral or intramuscular steroids: current/recent | 1031 (98) | 423 (41) | 244 (41) | 179 (40) |
NSAIDs: current | 942 (90) | 520 (55) | 296 (55) | 224 (55) |
csDMARDs: current | 1050 (100) | 193 (18) | 100 (17) | 93 (21) |
csDMARDs: ever | 1050 (100) | 238 (23) | 120 (20) | 118 (26) |
MTX starting dose (mg/week) | 1042 (99) | 10 (10, 15) | 10 (10, 15) | 10 (10, 15) |
Psychosocial factors | ||||
HADS anxiety | 986 (94) | 6 (3, 9) | 6 (3, 9) | 6 (3, 10) |
HADS depression | 987 (94) | 6 (3, 9) | 6 (3, 9) | 5 (2, 8) |
BMQ medication necessity | 942 (90) | 19 (17, 22) | 20 (17, 23) | 19 (17, 22) |
BMQ medication concerns | 949 (90) | 15 (13, 18) | 15 (12, 17) | 16 (13, 18) |
BMQ necessity-concerns | 923 (88) | 4 (1, 8) | 5 (1, 8) | 4 (1, 8) |
IPQ negative illness representation | 967 (92) | 560 (58) | 330 (59) | 230 (56) |